Elevation Oncology Inc reports results for the quarter ended December 31 - Earnings Summary

Elevation Oncology

06/03/2025 23:40

Elevation Oncology Inc ELEV.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -19 cents.  The mean expectation of eight analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -24 cents to -18 cents per share.

Reported revenue was zero​; analysts expected zero.

Elevation Oncology Inc's reported EPS for the quarter was a loss of 18 cents​.

The company reported a quarterly loss of $10.44 million.

Elevation Oncology Inc shares had fallen by 9.3% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 3% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Elevation Oncology Inc is $6.50

This summary was machine generated from LSEG data March 6 at 11:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.22
-0.18
Beat
Sep. 30 2024
-0.20
-0.22
Missed
Jun. 30 2024
-0.22
-0.18
Beat
Mar. 31 2024
-0.20
-0.23
Missed